Dergiler / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 4

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials LIVER

USA Multicentre UDCA USA Multicentre UDCA USA Multicentre UDCA USA Single centre UDCA

Sayfa
342–348
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Biochemical responses after 2 years may provide some information on disease progression and therapeutic response in PBC

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The natural history of primary biliary cirrhosis (PBC) is extremely variable.
📊
Temel Bulgular & Veri:Pooled estimates of biochemical measurements, histological scores and clinical outcomes associated with PBC were calculated in the placebo group.Results: Placebo-treated PBC patients displayed a significant decrease in serum alkaline phosphatase and very slight fluctuations in the other biochemical parameters during the 2-year follow-up.
💡
Sonuç & Katkı:Biochemical responses after 2 years may provide some information on disease progression and therapeutic response in PBC
🔬Tür:Laboratuvar & Saha Deneyi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The natural history of primary biliary cirrhosis (PBC) is extremely variable. The extraction and analysis of available information from placebo-treated patients in randomized controlled trials of PBC treatment would facilitate the study of the natural history of PBC. The aim of the present study was to determine important clinical information regarding the natural history of PBC patients without effective treatment.Materials and Methods: A search of the PubMed, EMBASE and Cochrane Library databases was performed by two authors. Twelve randomized placebo-controlled clinical trials for PBC patients without decompensated cirrhosis were retrieved for further review. Pooled estimates of biochemical measurements, histological scores and clinical outcomes associated with PBC were calculated in the placebo group.Results: Placebo-treated PBC patients displayed a significant decrease in serum alkaline phosphatase and very slight fluctuations in the other biochemical parameters during the 2-year follow-up. Meanwhile, histological progression was observed in 39.4% of the placebo-treated patients, and a moderate deterioration in histological scores was noted after 2 years. The pooled 2-year rates of death, transplantation and development of varices were 11.4%, 8.7% and 10.6%, respectively, in placebo-treated PBC patients.Conclusion: This review provides a foundation for further epidemiologic investigations in untreated patients and ursodeoxycholic acid-resistant patients with PBC. Biochemical responses after 2 years may provide some information on disease progression and therapeutic response in PBC

Abstract

The natural history of primary biliary cirrhosis (PBC) is extremely variable. The extraction and analysis of available information from placebo-treated patients in randomized controlled trials of PBC treatment would facilitate the study of the natural history of PBC. The aim of the present study was to determine important clinical information regarding the natural history of PBC patients without effective treatment.Materials and Methods: A search of the PubMed, EMBASE and Cochrane Library databases was performed by two authors. Twelve randomized placebo-controlled clinical trials for PBC patients without decompensated cirrhosis were retrieved for further review. Pooled estimates of biochemical measurements, histological scores and clinical outcomes associated with PBC were calculated in the placebo group.Results: Placebo-treated PBC patients displayed a significant decrease in serum alkaline phosphatase and very slight fluctuations in the other biochemical parameters during the 2-year follow-up. Meanwhile, histological progression was observed in 39.4% of the placebo-treated patients, and a moderate deterioration in histological scores was noted after 2 years. The pooled 2-year rates of death, transplantation and development of varices were 11.4%, 8.7% and 10.6%, respectively, in placebo-treated PBC patients.Conclusion: This review provides a foundation for further epidemiologic investigations in untreated patients and ursodeoxycholic acid-resistant patients with PBC. Biochemical responses after 2 years may provide some information on disease progression and therapeutic response in PBC

🔖

Bu Makaleye Atıf Yap

XU, P., Lİ, L., Lİ, G., YU, C., Lİ, Y. (2016). Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials LIVER. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 4, 342–348. https://ajindex.com/articles/411314

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cir- rhosis. Lancet 2011; 377: 1600-9. [CrossRef] Verma A, Jazrawi RP, Ahmed HA, et al. Optimum dose of urso- deoxycholic acid in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 1069-76. [CrossRef] Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014; 34: e31-8. [CrossRef] Al-Harthy N, Kumagi T. Natural history and management of pri- mary biliary cirrhosis. Hepat Med 2012; 4: 61-71.
  2. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011; 50: 1-10. [CrossRef] Floreani A, Caroli D, Variola A, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011; 31: 361-8. [CrossRef] Myers RP, Shaheen AA, Fong A, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50: 1884-92. [CrossRef] Baldursdottir TR, Bergmann OM, Jonasson JG, Ludviksson BR, Axelsson TA, Björnsson ES. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 2012; 24: 824-30. [CrossRef] Corpechot C, Chazouillères O, Poupon R. Early primary biliarycir- rhosis: biochemical response to treatment and prediction oflong- term outcome. J Hepatol 2011; 55: 1361-7. [CrossRef] Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary bili- ary cirrhosis. Hepatology 2008; 48: 871-7. [CrossRef] Yu CH, Xu CF, Ye H, Li L, Li YM. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16: 2435-9. [CrossRef] Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Pla- cebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepa- tol 2008; 6: 1243-8. [CrossRef] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34. [CrossRef] Vuoristo M, Färkkilä M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirr